Drug Profile


Alternative Names: CD-5789

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galderma
  • Developer Galderma; University of Texas M. D. Anderson Cancer Center
  • Class Antiacnes; Antineoplastics; Benzoic acids; Keratolytics; Pyrrolidines; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ichthyosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Ichthyosis
  • No development reported Cutaneous T cell lymphoma

Most Recent Events

  • 23 Feb 2017 Galderma completes a phase III trial in Acne vulgaris (In children, In adolescents, In adults) in USA, Czech Republic, Germany and Hungary (NCT02189629)
  • 07 Feb 2017 Galderma completes a phase-III trial in Acne vulgaris (In children, In adolescents, In adults) in USA, Czech Republic, Hungary, Poland, Romania, Russia, Spain, Ukraine (NCT02556788)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma(Early-stage disease) in USA (Topical, Cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top